Can artificial intelligence help fight addiction and improve medication adherence? AiCure nets $12M in Series A

New York-based AiCure, which holds 12 patents for artificially intelligent software platforms that aim to improve patient outcomes by targeting medication adherence,  announced the closing of a $12.25 million funding round Monday.

The company's software was built with help from $7 million in competitive grants from four National Institutes of Health organizations, awarded in order to spur tech developments that would have a significant impact on drug research and therapy. The National Institute of Drug Abuse awarded AiCure $1 million in 2014 to help launch a major study into the efficacy of using the company's platform to monitor and intervene with patients receiving medication as maintenance therapy for addiction.

Adherence to such therapies is associated with improved recovery, but often patients take improper doses or sell the drugs to others. To address this, AiCure's platform connects patients with artificial intelligence software via their devices that determines whether a medication is being taken as prescribed. The platform has shown to be feasible for use across various patient populations, including elderly patients and study participants in schizophrenia and HIV prevention trials, according to a news release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars